Bisphosphonates and bone diseases: past, present and future.
作者信息
Heymann Dominique
出版信息
Curr Pharm Des. 2010;16(27):2948-9. doi: 10.2174/138161210793563572.
Abstract
摘要
相似文献
1
Bisphosphonates and bone diseases: past, present and future.
Curr Pharm Des. 2010;16(27):2948-9. doi: 10.2174/138161210793563572.
2
Pharmacological diversity among drugs that inhibit bone resorption.
Curr Opin Pharmacol. 2015 Jun;22:115-30. doi: 10.1016/j.coph.2015.05.005. Epub 2015 Jun 3.
3
Bisphosphonates: effects on osteoblast.
Eur J Clin Pharmacol. 2012 Jul;68(7):1013-8. doi: 10.1007/s00228-012-1216-7. Epub 2012 Feb 9.
4
Bisphosphonate therapy in the treatment of multiple myeloma.
Curr Pharm Des. 2010;16(27):3028-36. doi: 10.2174/138161210793563608.
5
Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?
Future Oncol. 2015;11(21):2853-6. doi: 10.2217/fon.15.210. Epub 2015 Sep 25.
6
[The use of bisphosphonates for treating pathological states in orthopedics].
Chir Narzadow Ruchu Ortop Pol. 2008 Jul-Aug;73(4):266-73.
7
Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review.
Support Care Cancer. 2007 Nov;15(11):1243. doi: 10.1007/s00520-007-0244-9. Epub 2007 Mar 29.
8
[Bone targeting agents: bisphosphonates].
Bull Cancer. 2013 Nov;100(11):1199-206. doi: 10.1684/bdc.2013.1840.
9
Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.
Curr Pharm Des. 2010;16(27):2950-60. doi: 10.2174/138161210793563635.
10
Novel therapeutic targets in myeloma bone disease.
Br J Pharmacol. 2014 Aug;171(16):3765-76. doi: 10.1111/bph.12742.
引用本文的文献
1
Non-biological Antiresorptive: Bisphosphonates.
Indian J Orthop. 2023 Dec 8;57(Suppl 1):120-126. doi: 10.1007/s43465-023-01054-7. eCollection 2023 Dec.
2
Astaxanthin as a Potent Antioxidant for Promoting Bone Health: An Up-to-Date Review.
Antioxidants (Basel). 2023 Jul 24;12(7):1480. doi: 10.3390/antiox12071480.
3
Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective.
Bone Rep. 2018 Mar 15;8:104-109. doi: 10.1016/j.bonr.2018.03.003. eCollection 2018 Jun.
4
Inflammation, fracture and bone repair.
Bone. 2016 May;86:119-30. doi: 10.1016/j.bone.2016.02.020. Epub 2016 Mar 2.
5
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences.
J Bone Oncol. 2012 Apr 26;1(1):2-11. doi: 10.1016/j.jbo.2012.03.001. eCollection 2012 Jun.
本文引用的文献
1
Prevention and treatment of bone metastases.
Curr Pharm Des. 2010;16(27):2998-3006. doi: 10.2174/138161210793563581.
2
Nitrogen-containing bisphosphonates and cancer immunotherapy.
Curr Pharm Des. 2010;16(27):3007-2014. doi: 10.2174/138161210793563545.
3
Therapeutic approach of primary bone tumours by bisphosphonates.
Curr Pharm Des. 2010;16(27):2981-7. doi: 10.2174/138161210793563554.
4
Targeted therapy options for treatment of bone metastases; beyond bisphosphonates.
Curr Pharm Des. 2010;16(27):3015-27. doi: 10.2174/138161210793563536.
5
Alternative use of bisphosphonate therapy for rheumatic disease.
Curr Pharm Des. 2010;16(27):3045-52. doi: 10.2174/138161210793563626.
6
Bisphosphonate therapy in the treatment of multiple myeloma.
Curr Pharm Des. 2010;16(27):3028-36. doi: 10.2174/138161210793563608.
7
Assessment of bisphosphonate activity in vitro.
Curr Pharm Des. 2010;16(27):2970-80. doi: 10.2174/138161210793563644.
8
Combined therapies of bone disease with bisphosphonates.
Curr Pharm Des. 2010;16(27):2988-97. doi: 10.2174/138161210793563590.
9
Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.
Curr Pharm Des. 2010;16(27):2950-60. doi: 10.2174/138161210793563635.
10
Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
Curr Pharm Des. 2010;16(27):2961-9. doi: 10.2174/138161210793563617.
Zotero 插件